The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Mechanism of memantine block of NMDA‐activated channels in rat retinal ganglion cells: uncompetitive antagonism.
Open accessAbstract
1. N‐methyl‐D‐aspartic acid (NMDA)‐activated currents were recorded from dissociated rat retinal ganglion cells using whole‐cell recording. The NMDA open‐channel blocking drug memantine was evaluated for non‐competitive and/or uncompetitive components of antagonism. A rapid superfusion system was used to apply various drugs for kinetic analysis. 2. Dose‐response data revealed that memantine blocked 200 microM NMDA‐evoked responses with a 50% inhibition constant (IC50) of approximately 1 microM at ‐60 mV and an empirical Hill coefficient of approximately 1. The antagonism followed a bimolecular reaction process. This 1:1 stoichiometry is supported by the fact that the macroscopic blocking rate of memantine (kon) increased linearly with memantine concentration and the macroscopic unblocking rate (koff) was independent of it. The estimated pseudo‐first order rate constant for macroscopic blockade was 4 x 10(5) M‐1 S‐1 and the rate constant for unblocking was 0.44 s‐1. Both the blocking and unblocking actions of memantine were well fitted by a single exponential process. 3. The kon for 2 microM memantine decreased with decreasing concentrations of NMDA. By analysing kon behaviour, we estimate that memantine has minimal interaction with the closed‐unliganded state of the channel. As channel open probability (Po) approached zero, a small residual action of memantine may be explained by the presence of endogenous glutamate and glycine. 4. Memantine could be trapped within the NMDA‐gated channel if it was suddenly closed by fast washout of agonist. The measured gating process of channel activation and deactivation appeared at least 10‐20‐fold faster than the kinetics of memantine action. By combining the agonist and voltage dependence of antagonism, a trapping scheme was established for further kinetic analysis. 5. With low agonist concentrations, NMDA‐gated channels recovered slowly from memantine blockade. By analysing the probability of a channel remaining blocked, we found that memantine binding appeared to stabilize the open conformation of the blocked channel and did not affect ligand affinity. Validity of the "trapping model' and stabilization of the open conformation were further suggested by agreement between the predicted dose‐response curve for NMDA in the presence of 2 microM memantine and the empirically derived dose‐response relationship. 6. Based on simple molecular schemes, the degree of blockade at various concentrations of agonist for "pure' non‐competitive vs. uncompetitive inhibition was computer simulated. The measured degree of blockade by 6 microM memantine was close to ideal for pure uncompetitive antagonism. Taken together, we conclude that the predominant mechanism of open‐channel blockade by memantine is uncompetitive. In general, the relative magnitude of the dissociation rate of an open‐channel blocker from the open but blocked channel (the apparent off‐rate) compared with the rate of leaving the closed and blocker‐trapped state (the leak rate) will determine the contribution of uncompetitive vs. non‐competitive actions, respectively. 7. Millimolar internal Cs+ competed with memantine for binding in the NMDA‐gated channel, and reduced the association rate of memantine, but had no effect on the voltage dependence of the dissociation rate. After removal of Cs+, the calculated Ki for memantine remained voltage dependent. These observations would be difficult to reconcile with models in which memantine binds to a site outside the channel pore and instead strongly support the supposition that the blocking site for memantine is within the permeation pathway.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hamill, O. P., Marty, A., Neher, E., Sakmann, B., & Sigworth, F. J. (1981) · Pflügers Archiv - European Journal of Physiology · doi:10.1007/bf00656997 · Cited by 18,436
Down-Regulation of Na+/K+ATPase Activity by Human Parvovirus B19 Capsid Protein VP1
Almilaji, A., Szteyn, K., Fein, E., Pakladok, T., Munoz, C., Elvira, B., Towhid, S. T., Alesutan, I., Shumilina, E., Bock, C.-T., et al. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350083 · Cited by 8,675
Glutamate neurotoxicity and diseases of the nervous system
CHOI, D. (1988) · Neuron · doi:10.1016/0896-6273(88)90162-6 · Cited by 7,972
Regulation of the Voltage Gated K+ Channel Kv1.3 by Recombinant Human Klotho Protein
Almilaji, A., Honisch, S., Liu, G., Elvira, B., Ajay, S. S., Hosseinzadeh, Z., Ahmed, M., Munoz, C., Sopjani, M., & Lang, F. (2014) · Kidney and Blood Pressure Research · doi:10.1159/000368472 · Cited by 5,592
Magnesium gates glutamate-activated channels in mouse central neurones
Nowak, L., Bregestovski, P., Ascher, P., Herbet, A., & Prochiantz, A. (1984) · Nature · doi:10.1038/307462a0 · Cited by 4,043
Excitatory Amino Acids as a Final Common Pathway for Neurologic Disorders
Epstein, F. H., Lipton, S. A., & Rosenberg, P. A. (1994) · New England Journal of Medicine · doi:10.1056/nejm199403033300907 · Cited by 2,658
Self-citationThe anticonvulsant MK-801 is a potent N-methyl-D-aspartate antagonist.
Wong, E. H., Kemp, J. A., Priestley, T., Knight, A. R., Woodruff, G. N., & Iversen, L. L. (1986) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.83.18.7104 · Cited by 1,819
Excitatory amino acid neurotoxicity and neurodegenerative disease
Meldrum, B., & Garthwaite, J. (1990) · Trends in Pharmacological Sciences · doi:10.1016/0165-6147(90)90184-a · Cited by 1,771
Ionic Blockage of Sodium Channels in Nerve
Woodhull, A. M. (1973) · The Journal of General Physiology · doi:10.1085/jgp.61.6.687 · Cited by 1,569
Functional characterization of a heteromeric NMDA receptor channel expressed from cloned cDNAs
Meguro, H., Mori, H., Araki, K., Kushiya, E., Kutsuwada, T., Yamazaki, M., Kumanishi, T., Arakawa, M., Sakimura, K., & Mishina, M. (1992) · Nature · doi:10.1038/357070a0 · Cited by 798
Cited by
Glutamate receptor ion channels
Mayer, M. L. (2005) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2005.05.004 · Cited by 3,640
Glutamate Receptor Ion Channels: Structure, Regulation, and Function
Traynelis, S. F., Wollmuth, L. P., McBain, C. J., Menniti, F. S., Vance, K. M., Ogden, K. K., Hansen, K. B., Yuan, H., Myers, S. J., & Dingledine, R. (2010) · Pharmacological Reviews · doi:10.1124/pr.109.002451 · Cited by 3,568
The Glutamate Receptor Ion Channels
Dingledine, R., Borges, K., Bowie, D., & Traynelis, S. F. (1999) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01394-2 · Cited by 3,554
Brown, P. D., Pugh, S., Laack, N. N., Wefel, J. S., Khuntia, D., Meyers, C., Choucair, A., Fox, S., Suh, J. H., Roberge, D., et al. (2013) · Neuro-Oncology · doi:10.1093/neuonc/not114 · Cited by 958
Paradigm shift in neuroprotection by NMDA receptor blockade: memantine and beyond
Lipton, S. A. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd1958 · Cited by 909
Self-citationParsons, C. G., Danysz, W., & Quack, G. (1999) · Neuropharmacology · doi:10.1016/s0028-3908(99)00019-2 · Cited by 878
Structure, Function, and Pharmacology of Glutamate Receptor Ion Channels
Hansen, K. B., Wollmuth, L. P., Bowie, D., Furukawa, H., Menniti, F. S., Sobolevsky, A. I., Swanson, G. T., Swanger, S. A., Greger, I. H., Nakagawa, T., et al. (2021) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000131 · Cited by 686
Parsons, C. G., Stöffler, A., & Danysz, W. (2007) · Neuropharmacology · doi:10.1016/j.neuropharm.2007.07.013 · Cited by 707
Increased NMDA current and spine density in mice lacking the NMDA receptor subunit NR3A
Das, S., Sasaki, Y. F., Rothe, T., Premkumar, L. S., Takasu, M., Crandall, J. E., Dikkes, P., Conner, D. A., Rayudu, P. V., Cheung, W., et al. (1998) · Nature · doi:10.1038/30748 · Cited by 609
Self-citationOpioid-induced Hyperalgesia in Humans: Molecular Mechanisms and Clinical Considerations
Chu, L. F., Angst, M. S., & Clark, D. (2008) · The Clinical Journal of Pain · doi:10.1097/ajp.0b013e31816b2f43 · Cited by 575
Structure, function, and allosteric modulation of NMDA receptors
Hansen, K. B., Yi, F., Perszyk, R. E., Furukawa, H., Wollmuth, L. P., Gibb, A. J., & Traynelis, S. F. (2018) · Journal of General Physiology · doi:10.1085/jgp.201812032 · Cited by 573
Mechanism of action of memantine
JOHNSON, J., & KOTERMANSKI, S. (2006) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2005.09.007 · Cited by 502
The chemical biology of clinically tolerated NMDA receptor antagonists
Chen, H. V., & Lipton, S. A. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.03991.x · Cited by 474
Self-citationWhole-Brain Radiotherapy in the Management of Brain Metastasis
Khuntia, D., Brown, P., Li, J., & Mehta, M. P. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.6185 · Cited by 466
The Neuropharmacological Basis for the Use of Memantine in the Treatment of Alzheimer's Disease
Rogawski, M. A., & Wenk, G. L. (2003) · CNS Drug Reviews · doi:10.1111/j.1527-3458.2003.tb00254.x · Cited by 436
Lipton, S. A. (2004) · NeuroRX · doi:10.1602/neurorx.1.1.101 · Cited by 397
Self-citationXia, P., Chen, H.-S. V., Zhang, D., & Lipton, S. A. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.2488-10.2010 · Cited by 379
Self-citationSubunit- and site-specific pharmacology of the NMDA receptor channel
Yamakura, T., & Shimoji, K. (1999) · Progress in Neurobiology · doi:10.1016/s0301-0082(99)00007-6 · Cited by 311
Cellular Plasticity Cascades: Targets for the Development of Novel Therapeutics for Bipolar Disorder
Zarate, C. A., Singh, J., & Manji, H. K. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.10.021 · Cited by 274
Therapeutics of Neurotransmitters in Alzheimer’s Disease
Kandimalla, R., & Reddy, P. H. (2017) · Journal of Alzheimer’s Disease · doi:10.3233/jad-161118 · Cited by 268
Pathologically activated therapeutics for neuroprotection
Lipton, S. A. (2007) · Nature Reviews Neuroscience · doi:10.1038/nrn2229 · Cited by 257
Self-citationLipton, S. A. (2005) · Journal of Alzheimer's Disease · doi:10.3233/jad-2004-6s610 · Cited by 194
Self-citationGrossberg, G., & Thomas, S. (2009) · Clinical Interventions in Aging · doi:10.2147/cia.s6666 · Cited by 151
Galantamine potentiates the neuroprotective effect of memantine against NMDA‐induced excitotoxicity
Lopes, J. P., Tarozzo, G., Reggiani, A., Piomelli, D., & Cavalli, A. (2013) · Brain and Behavior · doi:10.1002/brb3.118 · Cited by 64
Hart, S. J., Visootsak, J., Tamburri, P., Phuong, P., Baumer, N., Hernandez, M., Skotko, B. G., Ochoa‐Lubinoff, C., Liogier D'Ardhuy, X., Kishnani, P. S., et al. (2017) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.38465 · Cited by 54
NMDA receptor antagonism: escalation of aggressive behavior in alcohol-drinking mice
Newman, E. L., Chu, A., Bahamón, B., Takahashi, A., DeBold, J. F., & Miczek, K. A. (2012) · Psychopharmacology · doi:10.1007/s00213-012-2734-9 · Cited by 46
Metadata
- Authors
- Chen, H. S., & Lipton, S. A.
- Venue
- The Journal of Physiology
- Publisher
- Wiley
- Published
- 1997-02-15
- Volume
- 499
- Issue
- 1
- Pages
- 27-46
- ISSN
- 0022-3751 (ISSN-L)
- 1469-7793
- OpenAlex
- W2056560960
- Cited by
- 282
- References
- 43
- FWCI
- 3.67
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.